Table 2 Treatment outcomes and exposure of all response-evaluable patients, those who did not proceed to SCT, and those who received maintenance

From: Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance

  All patients (N = 64) Patients who did not proceed to SCT (N = 41) Patients who received maintenance (N = 25)
Clinical outcome
Best confirmed response
ORR (CR + VGPR + PR) 56 (88) 33 (80) 25 (100)
    ≥VGPR 37 (58) 26 (63) 19 (76)
        CR 15 (23) 13 (32) 11 (44)
          sCR 6 (9) 4 (10) 4 (16)
    PR 41 (64) 20 (49) 14 (56)
        VGPR 22 (34) 13 (32) 8 (32)
          Near complete response 5 (8) 4 (10) 3 (12)
Minimal response 3 (5) 3 (7) 0
SD 3 (5) 3 (7) 0
PD 0 0 0
Median time to best response ≥VGPR, monthsa 4.9 6.6 8.5
Median time to best response sCR/CR, monthsb 5.6 5.6 5.8
Median PFS, months (95% CI) 35.4 (17.84, 44.12) 29.4 (17.71, 41.13) 37.2 (20.93, 46.00)
Median follow-up for OS, months 56.3 55.2 56.4
Median OS, months NE NE NE
Landmark OS rate, %
    1 year 94 90 100
    2 years 89 87 100
    4 years 84 82 92
Treatment exposure
Median cycles of ixazomib received, n (range) 7 (1–73) 17 (1–73) 41 (15–73)
Cycles of ixazomib received, n (%)
    ≥8 32 (49) 29 (69) 25 (100)
    ≥12 26 (40) 25 (60) 25 (100)
    ≥16 24 (37) 24 (57) 24 (96)
Median relative dose intensityc, %
    Ixazomib 96.3 96.3 96.6
    Lenalidomide 88.3 90 93.7
    Dexamethasone 92.5 83.3 83.3
Patients remaining on treatment, n (%) 5 (8) 5 (12) 5 (20)
  1. Patients who proceeded to SCT did not receive further ixazomib therapy and the best response reported did not include response post SCT
  2. CI confidence interval, CR complete response, NE not estimable, ORR overall response rate, OS overall survival, PD progressive disease, PFS progression-free survival, PR partial response, sCR stringent CR, SCT stem cell transplantation, SD stable disease, VGPR very good PR
  3. an = 37, 26, and 19 for all patients, those who did not receive SCT, and those who proceeded to maintenance, respectively
  4. bn = 15, 13, and 11 for all patients, those who did not receive SCT, and those who proceeded to maintenance, respectively
  5. cRelative dose intensity = 100 × (total amount of dose taken ÷ total planned dose over treated cycles), where total planned dose was calculated by (dose planned at enrollment × number of planned doses per cycle × the number of treated cycles). Number of planned doses per cycle was 3 for ixazomib, 21 for lenalidomide, and 4 for dexamethasone